mRNA COVID-19 Vaccine Less Protective in Elderly With Comorbidity
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69% against infection, 86% against related death
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69% against infection, 86% against related death
In this study, patients with escalating clinical risk factors for recurrence did not have escalating 24-hour urine test abnormalities.
Greater urologist density independently predicted lower prostate cancer mortality.
A randomized phase 3 trial revealed no significant difference in disease-free survival between extended and standard lymph node dissection during radical cystectomy for muscle-invasive urothelial…
Accelerated aging associated with increased risk for early-onset tumors, driven by lung, gastrointestinal, uterine cancers
Kidney or ureteral stones are larger and more likely to be symptomatic at presentation.
A phase 3 trial demonstrates a high rate of complete response with cretostimogene, an investigational immunotherapy administered intravesically.
Compared with oncologists, urologists report more barriers to using standard of care treatment intensification in the first-line setting for metastatic
The geographic distribution of the malignancy in Finland provided a clue to an upward trend.
Increased levels can cause harm, but clinicians can help their patients focus on nourishing their body rather than fearing nutrients by staying current on guidelines…
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.